



Blincyto

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ kg

Patient Height: _____ cm

Please indicate the place of service for the requested drug:

- Ambulatory Surgical Home Off Campus Outpatient Hospital
 On Campus Outpatient Hospital Office Pharmacy

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Blincyto SGM – 06/2021.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Criteria Questions:

1. What is the patient's diagnosis?
 B-cell precursor acute lymphoblastic leukemia (ALL)
 Other _____
2. What is the ICD-10 code? _____
3. Is this a request for continuation of therapy with the requested drug? Yes No *If No, skip to #5*
4. Is there evidence of unacceptable toxicity or disease progression on the current regimen?
 Yes No *No further questions*
5. Will Blincyto be used as a single agent with corticosteroids given as premedication prior to infusion?
 Yes No
6. Are the B-cells positive for CD19? **ACTION REQUIRED: If Yes, attach supporting chart note(s).**
 Yes No Unknown
7. Does the patient have Philadelphia chromosome positive, negative or like disease?
 Positive
 Negative, *skip to #12*
 Like, *skip to #14*
 Unknown
8. Is the patient's disease relapsed or refractory? Yes No
9. Did the patient have an inadequate response or intolerance to a tyrosine kinase inhibitor (e.g., imatinib, dasatinib)?
If Yes, no further questions Yes No
10. Did the patient have a less than complete response following induction therapy?
If Yes, no further questions Yes No
11. Will Blincyto be used for minimal residual disease positive (MRD+) disease after consolidation therapy?
 Yes No *No Further Questions*
12. Is the patient's disease relapsed or refractory? *If Yes, no further questions* Yes No
13. Will Blincyto be used as consolidation therapy for minimal residual disease positive (MRD+) disease after a complete response to induction therapy? *If Yes, no further questions* Yes No
14. Will Blincyto be used for minimal residual disease positive (MRD+) disease after consolidation therapy?
 Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Blincyto SGM – 06/2021.

**CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com**